Table 3.

Analysis of cardiac toxicity

^aAsymptomatic relative decline of LVEF ≥20% relative to baseline or asymptomatic relative decline <20% with LVEF <50%.

^bEpirubicin-induced cardiopathy.

^cSevere cardiogenic heart failure necessitating resuscitating measures.

^dArrhythmia (n = 2), dyspnea (n = 1).

^ePericarditis (n = 1), menace syndrome (n = 1).

Abbreviations: FEC, fluorouracil, epirubicin, and cyclophosphamide; FEC-D, fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel; LVEF, left ventricular ejection fraction; SAE, serious adverse event.